Suppr超能文献

哺乳动物速激肽配体-受体系统:中枢神经系统疾病的新兴靶点。

The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders.

机构信息

Receptor Pharmacology Unit, Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.

出版信息

CNS Neurol Disord Drug Targets. 2010 Nov;9(5):627-35. doi: 10.2174/187152710793361504.

Abstract

Our understanding of the complex signaling neurophysiology of the central nervous system has facilitated the exploration of potential novel receptor-ligand system targets for disorders of this most complex organ. In recent years, many relatively neglected receptor-ligand systems have been re-evaluated with respect to their ability to potently modulate discrete tracts in the central nervous system. One such system is the tachykinin (previously neurokinin) system. The multiple heptahelical G protein-coupled receptors and neuropeptide ligands that comprise this system may be significantly involved in more central nervous systems actions than previously thought, including sleep disorders, amyotrophic lateral sclerosis, Alzheimer's disease and Machado-Joseph disease. The development of our understanding of the role of the tachykinin receptor-ligand system in higher order central functions is likely to allow the creation of more specific and selective tachykinin-related neurotherapeutics.

摘要

我们对中枢神经系统复杂信号神经生理学的理解促进了对该最复杂器官疾病的潜在新型受体-配体系统靶标的探索。近年来,许多相对被忽视的受体-配体系统已经重新评估了其在调节中枢神经系统离散途径方面的强大能力。这样的系统之一是速激肽(以前称为神经激肽)系统。该系统包含的多种七螺旋 G 蛋白偶联受体和神经肽配体可能比以前认为的更广泛地参与中枢神经系统的作用,包括睡眠障碍、肌萎缩侧索硬化症、阿尔茨海默病和 Machado-Joseph 病。我们对速激肽受体-配体系统在高级中枢功能中的作用的理解的发展,可能会允许创造更特异和选择性的速激肽相关神经治疗。

相似文献

1
The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders.
CNS Neurol Disord Drug Targets. 2010 Nov;9(5):627-35. doi: 10.2174/187152710793361504.
2
The mammalian tachykinin receptors.
Gen Pharmacol. 1995 Sep;26(5):911-44. doi: 10.1016/0306-3623(94)00292-u.
3
Tachykinins and tachykinin receptors in bone.
Microsc Res Tech. 2002 Jul 15;58(2):91-7. doi: 10.1002/jemt.10123.
4
Tachykinins and the cardiovascular system.
Curr Drug Targets. 2006 Aug;7(8):1031-42. doi: 10.2174/138945006778019291.
6
Mammalian tachykinins and uterine smooth muscle: the challenge escalates.
Eur J Pharmacol. 2004 Oct 1;500(1-3):15-26. doi: 10.1016/j.ejphar.2004.07.007.
7
Tachykinin receptors in the small intestine of the cane toad (Bufo marinus): a radioligand binding and functional study.
Naunyn Schmiedebergs Arch Pharmacol. 1998 Jun;357(6):692-700. doi: 10.1007/pl00005226.
8
New challenges in the study of the mammalian tachykinins.
Peptides. 2005 Aug;26(8):1356-68. doi: 10.1016/j.peptides.2005.03.030. Epub 2005 Apr 20.
10
Tachykinins and tachykinin receptors: a growing family.
Life Sci. 2004 Feb 6;74(12):1445-63. doi: 10.1016/j.lfs.2003.09.039.

引用本文的文献

3
Transcriptional Pathology Evolves over Time in Rat Hippocampus after Lateral Fluid Percussion Traumatic Brain Injury.
Neurotrauma Rep. 2021 Nov 23;2(1):512-525. doi: 10.1089/neur.2021.0021. eCollection 2021.
4
Neuropeptides: Roles and Activities as Metal Chelators in Neurodegenerative Diseases.
J Phys Chem B. 2021 Mar 25;125(11):2796-2811. doi: 10.1021/acs.jpcb.0c11151. Epub 2021 Feb 11.
5
Update on the pathophysiology of cluster headache: imaging and neuropeptide studies.
J Pain Res. 2019 Jan 4;12:269-281. doi: 10.2147/JPR.S175312. eCollection 2019.
6
Pain in knee osteoarthritis is associated with variation in the neurokinin 1/substance P receptor (TACR1) gene.
Eur J Pain. 2017 Aug;21(7):1277-1284. doi: 10.1002/ejp.1027. Epub 2017 May 11.
8
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.
Br J Pharmacol. 2013 Dec;170(8):1459-581. doi: 10.1111/bph.12445.
10
Interactions between kisspeptins and neurokinin B.
Adv Exp Med Biol. 2013;784:325-47. doi: 10.1007/978-1-4614-6199-9_15.

本文引用的文献

1
Alzheimer's disease.
N Engl J Med. 2010 Jan 28;362(4):329-44. doi: 10.1056/NEJMra0909142.
2
Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1607-14. doi: 10.1517/17425250903451675.
3
SP protects cerebellar granule cells against beta-amyloid-induced apoptosis by down-regulation and reduced activity of Kv4 potassium channels.
Neuropharmacology. 2010 Jan;58(1):268-76. doi: 10.1016/j.neuropharm.2009.06.029. Epub 2009 Jul 2.
4
Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.
Expert Opin Pharmacother. 2009 Jul;10(10):1561-70. doi: 10.1517/14656560902988510.
5
Pharmacological actions of eledoisin on extravascular smooth muscle.
Br J Pharmacol Chemother. 1962 Oct;19(2):337-54. doi: 10.1111/j.1476-5381.1962.tb01198.x.
7
Targeting TNF-alpha receptors for neurotherapeutics.
Trends Neurosci. 2008 Oct;31(10):504-11. doi: 10.1016/j.tins.2008.07.005. Epub 2008 Sep 4.
9
Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.
Neuropharmacology. 2008 Jun;54(7):1143-52. doi: 10.1016/j.neuropharm.2008.03.005. Epub 2008 Mar 18.
10
Genetic background influences the behavioural and molecular consequences of neurokinin-1 receptor knockout.
Eur J Neurosci. 2008 Feb;27(3):683-90. doi: 10.1111/j.1460-9568.2008.06043.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验